ACS Publications. Most Trusted. Most Cited. Most Read

OR SEARCH CITATIONS

My Activity
Publications
CONTENT TYPES

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Med. Chem. 2017, 60, 15, 6461-6479
RETURN TO ISSUEPerspectiveNEXT
ADDITION / CORRECTIONThis article has been corrected. View the notice.

Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection

View Author Information
† School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China
‡ Molecular Design and Chemical Biology, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai 201203, China
*For G.L.: phone, +86 10 62797740; E-mail, [email protected]
*For S.F.Y.: phone, +86 21 29846888; E-mail, [email protected]
Cite this: J. Med. Chem. 2017, 60, 15, 6461–6479
Publication Date (Web):April 6, 2017
https://doi.org/10.1021/acs.jmedchem.6b01442
Copyright © 2017 American Chemical Society
Request reuse permissions

    Article Views

    5074

    Altmetric

    -

    Citations

    64
    LEARN ABOUT THESE METRICS
    Read OnlinePDF (2 MB)
    Get e-Alerts
    SUBJECTS:

    Abstract

    Abstract Image

    For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis. We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics. A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogues, inhibitors of viral ribonuclease H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products. Compounds that exert their antiviral activities mainly through host factors and immunomodulation, such as host targeting agents (HTAs), programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and Toll-like receptor (TLR) agonists, are also discussed. In this Perspective, we hope to provide an overview, albeit by no means being comprehensive, for the recent development of novel therapeutic agents for the treatment of chronic HBV infection, which not only are able to sustainably suppress viral DNA but also aim to achieve functional cure warranted by HBsAg loss and ultimately lead to virus eradication and cure of hepatitis B.

    Cited By

    This article is cited by 64 publications.

    1. Xin Li, Zhigao Zhang, Yang Chen, Bin Wang, Guimei Yang, Xiangbin Xu, Baihui Yechao, Dongdong Bai, Binqiang Feng, Yuchang Mao, Jun Feng, Chang Bai, Feng He, Weikang Tao. Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator. ACS Medicinal Chemistry Letters 2022, 13 (3) , 507-512. https://doi.org/10.1021/acsmedchemlett.2c00002
    2. Jinsheng Zhou, Adam Zlotnick, Stephen C. Jacobson. Disassembly of Single Virus Capsids Monitored in Real Time with Multicycle Resistive-Pulse Sensing. Analytical Chemistry 2022, 94 (2) , 985-992. https://doi.org/10.1021/acs.analchem.1c03855
    3. Wuhong Chen, Feifei Liu, Qiliang Zhao, Xinna Ma, Dong Lu, Heng Li, Yanping Zeng, Xiankun Tong, Limin Zeng, Jia Liu, Li Yang, Jianping Zuo, Youhong Hu. Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors. Journal of Medicinal Chemistry 2020, 63 (15) , 8134-8145. https://doi.org/10.1021/acs.jmedchem.0c00346
    4. Andrew D. Huber, Dallas L. Pineda, Dandan Liu, Kelsey N. Boschert, Anna T. Gres, Jennifer J. Wolf, Emily M. Coonrod, Jing Tang, Thomas G. Laughlin, Qiongying Yang, Maritza N. Puray-Chavez, Juan Ji, Kamalendra Singh, Karen A. Kirby, Zhengqiang Wang, Stefan G. Sarafianos. Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. ACS Infectious Diseases 2019, 5 (5) , 750-758. https://doi.org/10.1021/acsinfecdis.8b00235
    5. Panagiotis Kondylis, Christopher J. Schlicksup, Sarah P. Katen, Lye Siang Lee, Adam Zlotnick, Stephen C. Jacobson. Evolution of Intermediates during Capsid Assembly of Hepatitis B Virus with Phenylpropenamide-Based Antivirals. ACS Infectious Diseases 2019, 5 (5) , 769-777. https://doi.org/10.1021/acsinfecdis.8b00290
    6. Li Yang, Feifei Liu, Xiankun Tong, Daniel Hoffmann, Jianping Zuo, Mengji Lu. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infectious Diseases 2019, 5 (5) , 713-724. https://doi.org/10.1021/acsinfecdis.8b00337
    7. Yameng Pei, Chunting Wang, Haijing Ben, Lei Wang, Yao Ma, Qingyan Ma, Ye Xiang, Linqi Zhang, Gang Liu. Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay. ACS Infectious Diseases 2019, 5 (5) , 778-787. https://doi.org/10.1021/acsinfecdis.9b00030
    8. Panagiotis Kondylis, Christopher J. Schlicksup, Nicholas E. Brunk, Jinsheng Zhou, Adam Zlotnick, Stephen C. Jacobson. Competition between Normative and Drug-Induced Virus Self-Assembly Observed with Single-Particle Methods. Journal of the American Chemical Society 2019, 141 (3) , 1251-1260. https://doi.org/10.1021/jacs.8b10131
    9. Panagiotis Kondylis, Christopher J. Schlicksup, Adam Zlotnick, Stephen C. Jacobson. Analytical Techniques to Characterize the Structure, Properties, and Assembly of Virus Capsids. Analytical Chemistry 2019, 91 (1) , 622-636. https://doi.org/10.1021/acs.analchem.8b04824
    10. Song Feng, Lu Gao, Xingchun Han, Taishan Hu, Yimin Hu, Haixia Liu, Andrew W. Thomas, Zhipeng Yan, Song Yang, John A. T. Young, Hongying Yun, Wei Zhu, Hong C. Shen. Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection. ACS Infectious Diseases 2018, 4 (3) , 257-277. https://doi.org/10.1021/acsinfecdis.7b00144
    11. Xiaoyu Shao, Shujing Xu, Xufeng Wan, Yang Zhou, Shuo Wang, Shuo Wu, Yuhuan Li, Xinyong Liu, Peng Zhan. Medicinal chemistry strategies in the discovery and optimization of HBV core protein allosteric modulators (2018–2022 update). Chinese Chemical Letters 2023, 34 (11) , 108349. https://doi.org/10.1016/j.cclet.2023.108349
    12. Elena Detta, Angelica Corcuera, Andreas Urban, Thomas Goldner, Susanne Bonsmann, Florian Engel, Marina M. May, Helmut Buschmann, Mauro Fianchini, Esther Alza, Miquel A. Pericàs, Pavel A. Pushkarev, Anatolii O. Varenyk, Taras Y. Yakovyuk, Anton A. Homon, Pavlo A. Sokoliuk, Radomyr Smaliy, Alastair Donald. Structure-based Design of Novel Hepatitis B Virus Capsid Assembly Modulators. Bioorganic & Medicinal Chemistry Letters 2023, 93 , 129412. https://doi.org/10.1016/j.bmcl.2023.129412
    13. Yiyang Qin, Shengdan Wang, Yunwen Wang, Yuan Wang, Xuefen Tao, Hui Zhao, Hao Wang, Shuang Yu, Rong Sheng. Pharmacophore-Based Virtual Screening and Structural Modification of Novel Benzamide Derivatives as HBV Capsid Assembly Modulators. Biological and Pharmaceutical Bulletin 2023, 46 (9) , 1277-1288. https://doi.org/10.1248/bpb.b23-00242
    14. Bo Qin, Shu Shen, Juan Lai, Wei Yang, Lili Feng, Jiefeng Ding. Inhibition of Hepatitis B Virus (HBV) replication and antigen expression by Brucea javanica (L.) Merr. oil emulsion. Frontiers in Cellular and Infection Microbiology 2023, 13 https://doi.org/10.3389/fcimb.2023.1193775
    15. Jing Chen, Li Li, Qi Yin, Tao Shen. A review of epidemiology and clinical relevance of Hepatitis B virus genotypes and subgenotypes. Clinics and Research in Hepatology and Gastroenterology 2023, 97 , 102180. https://doi.org/10.1016/j.clinre.2023.102180
    16. Mengying Guan, Yuan Wang, Yunwen Wang, Na Chen, Shu Shi, Rong Sheng. Discovery of 5‐alkyl‐2‐pyrazol‐oxazolidin‐4‐one derivatives as novel hepatitis B virus capsid assembly modulators. Archiv der Pharmazie 2023, 356 (6) https://doi.org/10.1002/ardp.202200592
    17. Zhengcheng Liang, Yongqing Tan, Yunhou Huang, Taoyuan Liang, Wanxing Wei, Mian Wang, Kaichuang Shi. Design and Synthesis of (3‐Phenylisoxazol‐5‐yl)methanimine Derivatives as Hepatitis B Virus Inhibitors. Chemistry & Biodiversity 2023, 20 (3) https://doi.org/10.1002/cbdv.202201247
    18. Priya Darshani, Shreya Sen Sarma, Amit K. Srivastava, Rinku Baishya, Deepak Kumar. Anti-viral triterpenes: a review. Phytochemistry Reviews 2022, 21 (6) , 1761-1842. https://doi.org/10.1007/s11101-022-09808-1
    19. Mark S. Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T. Nguyen, Eugene R. Schiff, Hie-Won L. Hann, Douglas T. Dieterich, Ronald G. Nahass, James S. Park, Sing Chan, Steven-Huy B. Han, Edward J. Gane, Michael Bennett, Katia Alves, Marc Evanchik, Ran Yan, Qi Huang, Uri Lopatin, Richard Colonno, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Ira M. Jacobson, Walid S. Ayoub, Frank Weilert, Natarajan Ravendhran, Alnoor Ramji, Paul Yien Kwo, Magdy Elkhashab, Tarek Hassanein, Ho S. Bae, Jacob P. Lalezari, Scott K. Fung, Man-Fung Yuen. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. Journal of Hepatology 2022, 77 (5) , 1265-1275. https://doi.org/10.1016/j.jhep.2022.05.027
    20. Oya Unsal Tan, Jan Moncol, David Durantel. Design, Synthesis and Evaluation of Novel 4‐(4‐Chlorobenzyl)‐6‐methylpyridazin‐3(2 H )‐one Derivatives as Hepatitis B Virus Inhibitors. ChemistrySelect 2022, 7 (40) https://doi.org/10.1002/slct.202203164
    21. Leda Ivanova Bencheva, Lorena Donnici, Luca Ferrante, Adolfo Prandi, Roberta Sinisi, Marilenia De Matteo, Pietro Randazzo, Matteo Conti, Pietro Di Lucia, Elisa Bono, Leonardo Giustini, Maria Vittoria Orsale, Alexandros Patsilinakos, Edith Monteagudo, Matteo Iannacone, Vincenzo Summa, Luca G. Guidotti, Raffaele De Francesco, Romano Di Fabio. Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators. Bioorganic & Medicinal Chemistry Letters 2022, 73 , 128904. https://doi.org/10.1016/j.bmcl.2022.128904
    22. Yunwen Wang, Shendan Wang, Xuefen Tao, Yuan Wang, Yuxuan Wu, Na Chen, Chenxian Hu, Hao Wang, Shuang Yu, Rong Sheng. The SAR-based development of small molecular HBV capsid assembly modulators. Medicinal Chemistry Research 2022, 31 (9) , 1414-1430. https://doi.org/10.1007/s00044-022-02936-5
    23. Yanbin Hu, Fei Sun, Qiang Yuan, Jinhua Du, Lihong Hu, Zhengxian Gu, Qiong Zhou, Xiaoting Du, Shibo He, Ya Sun, Qian Wang, Lirong Fan, Lina Wang, Shaohua Qin, Shuhui Chen, Jian Li, Wenqiang Wu, John Mao, Yixin Zhou, Qiaoyun Zhou, George Zhang, Charles Z. Ding. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. Bioorganic & Medicinal Chemistry Letters 2022, 30 , 128977. https://doi.org/10.1016/j.bmcl.2022.128977
    24. Xiaoyu Qin, Lu Yang, Xican Ma, Bin Jiang, Shuo Wu, Apeng Wang, Shijie Xu, Wenhao Wu, Huijuan Song, Na Du, Kai Lv, Yuhuan Li, Mingliang Liu. Identification of dihydroquinolizinone derivatives with cyclic ether moieties as new anti-HBV agents. European Journal of Medicinal Chemistry 2022, 238 , 114518. https://doi.org/10.1016/j.ejmech.2022.114518
    25. Angelica Corcuera, Alastair Donald, Andreas Urban. Direct‐Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection. 2022, 229-252. https://doi.org/10.1002/9783527810697.ch9
    26. Kai Lv, Shuo Wu, Zeyu Tao, Aoyu Wang, Shijie Xu, Lu Yang, Qiang Gao, Apeng Wang, Xiaoyu Qin, Bin Jiang, Wenhao Wu, Xuedong Jia, Yuhuan Li, Jiandong Jiang, Mingliang Liu. Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators. European Journal of Medicinal Chemistry 2022, 228 , 113974. https://doi.org/10.1016/j.ejmech.2021.113974
    27. Xiaoyu Qin, Lu Yang, Xican Ma, Bin Jiang, Shuo Wu, Apeng Wang, Shijie Xu, Wenhao Wu, Huijuan Song, Na Du, Kai Lv, Yu-huan Li, Mingliang Liu. Identification of Dihydroquinolizinone Derivatives with Cyclic Ether Moieties as New Anti-HBV Agents. SSRN Electronic Journal 2022, 2 https://doi.org/10.2139/ssrn.4068606
    28. Farooq‐Ahmad Khan, Rahila Khanam, Muhammad Wasim Qasim, Yan Wang, Zi‐Hua Jiang. Improved Synthesis of D‐Isoglutamine: Rapid Access to Desmuramyl Analogues of Muramyl Dipeptide for the Activation of Intracellular NOD2 Receptor and Vaccine Adjuvant Applications. European Journal of Organic Chemistry 2021, 2021 (48) , 6688-6699. https://doi.org/10.1002/ejoc.202101170
    29. Manabu Yamasaki, Norie Matsuda, Kazuaki Matoba, Saki Kondo, Yumi Kanegae, Izumu Saito, Akio Nomoto. Acetophenone 4-nitrophenylhydrazone inhibits Hepatitis B virus replication by modulating capsid assembly. Virus Research 2021, 306 , 198565. https://doi.org/10.1016/j.virusres.2021.198565
    30. Nathália Alves Araújo de Almeida, Camilla Rodrigues de Almeida Ribeiro, Jéssica Vasques Raposo, Vanessa Salete de Paula. Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. Viruses 2021, 13 (5) , 822. https://doi.org/10.3390/v13050822
    31. Georgia-Myrto Prifti, Dimitrios Moianos, Erofili Giannakopoulou, Vasiliki Pardali, John Tavis, Grigoris Zoidis. Recent Advances in Hepatitis B Treatment. Pharmaceuticals 2021, 14 (5) , 417. https://doi.org/10.3390/ph14050417
    32. Piet Herdewijn, Weijie Gu, Erik De Clercq. Anti‐DNA Virus Agents. 2021, 1-41. https://doi.org/10.1002/0471266949.bmc237.pub2
    33. Yue Ma, Estrella Frutos-Beltrán, Dongwei Kang, Christophe Pannecouque, Erik De Clercq, Luis Menéndez-Arias, Xinyong Liu, Peng Zhan. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chemical Society Reviews 2021, 50 (7) , 4514-4540. https://doi.org/10.1039/D0CS01084G
    34. Yuan Wang, Zhe Wang, Jiacheng Liu, Yunwen Wang, Rui Wu, Rong Sheng, Tingjun Hou. Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays. Bioorganic & Medicinal Chemistry 2021, 36 , 116096. https://doi.org/10.1016/j.bmc.2021.116096
    35. Guo-Qing Yin, Jun Li, Bei Zhong, Yong-Fong Yang, Mao-Rong Wang. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World Journal of Gastroenterology 2021, 27 (8) , 666-676. https://doi.org/10.3748/wjg.v27.i8.666
    36. Fenju Wei, Edeildo Ferreira da Silva-Júnior, Xinyong Liu, Peng Zhan. HIV-1 and HBV RNase H as Metal-Chelating Inhibitors: Discovery and Medicinal Chemistry Strategies. 2021, 585-602. https://doi.org/10.1007/978-3-030-71165-8_28
    37. Jing Li, Haitao Chen, Jiaxuan Chen, Bin Zhou, Jinlin Hou, De-Ke Jiang. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. Pharmacogenomics and Personalized Medicine 2021, Volume 14 , 1505-1515. https://doi.org/10.2147/PGPM.S337962
    38. Abdolkarim Farrokhzadeh, Farideh Badichi Akher, Fisayo A. Olotu, Fanie R. Van Heerden. Impact of HEC72702 chirality on the selective inhibition of hepatitis B virus capsid dimer: A dynamics–structure–energetics perspective. Chemical Biology & Drug Design 2021, 97 (1) , 167-183. https://doi.org/10.1111/cbdd.13771
    39. Zhanfei Chen, Yiyin Chen, Lirong Peng, Xiaoqian Wang, Nanhong Tang. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. Journal for ImmunoTherapy of Cancer 2020, 8 (2) , e001377. https://doi.org/10.1136/jitc-2020-001377
    40. Ellen Bak, Jennifer T. Miller, Andrea Noronha, John Tavis, Emilio Gallicchio, Ryan P. Murelli, Stuart F. J. Le Grice. 3,7-Dihydroxytropolones Inhibit Initiation of Hepatitis B Virus Minus-Strand DNA Synthesis. Molecules 2020, 25 (19) , 4434. https://doi.org/10.3390/molecules25194434
    41. Fenju Wei, Dongwei Kang, Srinivasulu Cherukupalli, Waleed A. Zalloum, Tao Zhang, Xinyong Liu, Peng Zhan. Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents. Expert Opinion on Therapeutic Patents 2020, 30 (9) , 715-721. https://doi.org/10.1080/13543776.2020.1801641
    42. Kaku Goto, Hironori Nishitsuji, Masaya Sugiyama, Nao Nishida, Masashi Mizokami, Kunitada Shimotohno. Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation. International Journal of Molecular Sciences 2020, 21 (16) , 5661. https://doi.org/10.3390/ijms21165661
    43. Maria Gerasi, Efseveia Frakolaki, Georgios Papadakis, Anna Chalari, Nikolaos Lougiakis, Panagiotis Marakos, Nicole Pouli, Niki Vassilaki. Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines. Bioorganic Chemistry 2020, 98 , 103580. https://doi.org/10.1016/j.bioorg.2020.103580
    44. Kai Lv, Wenyan Li, Shuo Wu, Yunhe Geng, Apeng Wang, Lu Yang, Menghao Huang, Kushan Chowdhury, Yuhuan Li, Mingliang Liu. Amino acid prodrugs of NVR3-778: Design, synthesis and anti-HBV activity. Bioorganic & Medicinal Chemistry Letters 2020, 30 (9) , 127103. https://doi.org/10.1016/j.bmcl.2020.127103
    45. Haitao Chen, Jian Sun, Bin Zhou, Jinxin Peng, Qing Xie, Xieer Liang, Rong Fan, Carly Conran, Jianfeng Xu, Yuan Ji, Xinxin Zhang, Li Sun, Jidong Jia, Guiqiang Wang, Jinlin Hou, De‐Ke Jiang. A missense variant in complement factor B ( CFB ) is a potential predictor of 24‐week off‐treatment response to PegIFNα therapy in Chinese HBeAg‐positive chronic hepatitis B patients. Alimentary Pharmacology & Therapeutics 2020, 51 (4) , 469-478. https://doi.org/10.1111/apt.15624
    46. Víctor Deioxes Escandón-Felizzola. Recomendaciones en el tratamiento actual de la infección crónica por el virus de la hepatitis B. Hepatología 2020, , 36-54. https://doi.org/10.52784/27112330.114
    47. Kai Lv, Shuo Wu, Wenyan Li, Yunhe Geng, Meng Wu, Jinming Zhou, Yuhuan Li, Qiang Gao, Mingliang Liu. Design, synthesis and anti-HBV activity of NVR3-778 derivatives. Bioorganic Chemistry 2020, 94 , 103363. https://doi.org/10.1016/j.bioorg.2019.103363
    48. Haitao Chen, Jian Sun, Bin Zhou, Qing Xie, Xier Liang, Rong Fan, Carly Conran, Jianfeng Xu, Yuan Ji, Xinxin Zhang, Li Sun, Jidong Jia, Guiqiang Wang, Jinlin Hou, De-Ke Jiang. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clinical Gastroenterology and Hepatology 2020, 18 (1) , 196-204.e8. https://doi.org/10.1016/j.cgh.2019.04.044
    49. Enzo Tramontano, Angela Corona, Luis Menéndez-Arias. Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus. Antiviral Research 2019, 171 , 104613. https://doi.org/10.1016/j.antiviral.2019.104613
    50. Jingying Qiu, Wang Chen, Yinpeng Zhang, Qingqing Zhou, Jing Chen, Lihua Yang, Jian Gao, Xiaoke Gu, Daoquan Tang. Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. European Journal of Medicinal Chemistry 2019, 176 , 41-49. https://doi.org/10.1016/j.ejmech.2019.05.014
    51. Hannah M. Lee, Bubu A. Banini. Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options in Gastroenterology 2019, 17 (2) , 271-291. https://doi.org/10.1007/s11938-019-00236-3
    52. Bhavitavya Nijampatnam, Dennis C Liotta. Recent advances in the development of HBV capsid assembly modulators. Current Opinion in Chemical Biology 2019, 50 , 73-79. https://doi.org/10.1016/j.cbpa.2019.02.009
    53. Li Ting Song, Rui Rui Liu, Hong Lin Zhai, Ya Jie Meng, Min Zhu. Molecular mechanisms of tetrahydropyrrolo[1,2-c]pyrimidines as HBV capsid assembly inhibitors. Archives of Biochemistry and Biophysics 2019, 663 , 1-10. https://doi.org/10.1016/j.abb.2018.12.029
    54. Jing Tang, Andrew D. Huber, Dallas L. Pineda, Kelsey N. Boschert, Jennifer J. Wolf, Jayakanth Kankanala, Jiashu Xie, Stefan G. Sarafianos, Zhengqiang Wang. 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. European Journal of Medicinal Chemistry 2019, 164 , 179-192. https://doi.org/10.1016/j.ejmech.2018.12.047
    55. Luca Ferrari, Stefan G. D. Rüdiger. Hsp90 Chaperone in Disease. 2019, 473-491. https://doi.org/10.1007/978-3-030-23158-3_21
    56. Sun Hong Yoo, Jung Hyun Kwon. New Potential Therapies for Chronic Hepatitis B. The Korean Journal of Gastroenterology 2019, 74 (5) , 267. https://doi.org/10.4166/kjg.2019.74.5.267
    57. Nicky Helsen, Tom Vervoort, Joris Vandenbossche, Oliver Lenz, Mario Monshouwer, Frederik Pauwels, Jan Snoeys. Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778. Antimicrobial Agents and Chemotherapy 2018, 62 (11) https://doi.org/10.1128/AAC.01497-18
    58. Uma S. Singh, Varughese A. Mulamoottil, Chung K. Chu. 2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants. Medicinal Research Reviews 2018, 38 (3) , 977-1002. https://doi.org/10.1002/med.21490
    59. Lauriane Lecoq, Shishan Wang, Thomas Wiegand, Stéphane Bressanelli, Michael Nassal, Beat H. Meier, Anja Böckmann. Solid-state [13C–15N] NMR resonance assignment of hepatitis B virus core protein. Biomolecular NMR Assignments 2018, 12 (1) , 205-214. https://doi.org/10.1007/s12104-018-9810-y
    60. G. Lin, W. Zhuang, X.H. Chen, C. Huang, X.D. Lin, Y.J. Huang, C. Li. Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B. Annals of Oncology 2018, 29 (2) , 516-517. https://doi.org/10.1093/annonc/mdx694
    61. Christopher John Schlicksup, Joseph Che-Yen Wang, Samson Francis, Balasubramanian Venkatakrishnan, William W Turner, Michael VanNieuwenhze, Adam Zlotnick. Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids. eLife 2018, 7 https://doi.org/10.7554/eLife.31473
    62. Małgorzata Patejko, Wiktoria Struck-Lewicka, Danuta Siluk, Małgorzata Waszczuk-Jankowska, Michał J. Markuszewski. Urinary Nucleosides and Deoxynucleosides. 2018, 1-51. https://doi.org/10.1016/bs.acc.2017.10.001
    63. Shuye Zhang, Fusheng Wang, Zheng Zhang. Current advances in the elimination of hepatitis B in China by 2030. Frontiers of Medicine 2017, 11 (4) , 490-501. https://doi.org/10.1007/s11684-017-0598-4
    64. Vincent Soriano, Pablo Barreiro, Laura Benitez, Jose M. Peña, Carmen de Mendoza. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017, 26 (7) , 843-851. https://doi.org/10.1080/13543784.2017.1333105
    Download PDF

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect